Research programme: cystic fibrosis therapy - Salus TherapeuticsAlternative Names: Antisense drug therapies research programme - Salus Therapeutics; Cystic fibrosis therapy research programme - Salus Therapeutics; Research programme: antisense drug therapies - Salus Therapeutics
Latest Information Update: 31 May 2006
At a glance
- Originator Genta
- Developer Genta (CEASED)
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cystic fibrosis
Most Recent Events
- 13 Nov 2000 Preclinical development for Cystic fibrosis in USA (Unknown route)